Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment
File Type:
PDFItem Type:
Journal ArticleDate:
2018Author:
Access:
openAccessCitation:
Noonan, S. A., Morrissey, M. E., Martin, P., Biniecka, M., O'Meachair, S., Maguire, A., Tosetto, M., Nolan, B., Hyland, J., Sheahan, K., O'Donoghue, D., Mulcahy, H., Fennelly, D., O'Sullivan, J. Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment, Oncotarget, 2018, 9, 12, 10536 - 10548Download Item:
Abstract:
Despite treatment of patients with metastatic colorectal cancer (mCRC) with bevacizumab plus chemotherapy, response rates are modest and there are no biomarkers available that will predict response. The aim of this study was to assess if markers associated with three interconnected cancer-associated biological processes, specifically angiogenesis, inflammation and oxidative damage, could stratify the survival outcome of this cohort.
Levels of angiogenesis, inflammation and oxidative damage markers were assessed in pre-bevacizumab resected tumour and serum samples of mCRC patients by dual immunofluorescence, immunohistochemistry and ELISA.
This study identified that specific markers of angiogenesis, inflammation and oxidative damage stratify survival of patients on this anti-angiogenic treatment. Biomarkers of immature tumour vasculature (% IMM, p=0.026, n=80), high levels of oxidative damage in the tumour epithelium (intensity of 8-oxo-dG in nuclear and cytoplasmic compartments, p=0.042 and 0.038 respectively, n=75) and lower systemic pro-inflammatory cytokines (IL6 and IL8, p=0.053 and 0.049 respectively, n=61) significantly stratify with median overall survival (OS).
In summary, screening for a panel of biomarkers for high levels of immature tumour vasculature, high levels of oxidative DNA damage and low levels of systemic pro-inflammatory cytokines may be beneficial in predicting enhanced survival outcome following bevacizumab treatment for mCRC.
Author's Homepage:
http://people.tcd.ie/osullij4Description:
PUBLISHED
Author: O'Sullivan, Jacintha
Type of material:
Journal ArticleCollections
Series/Report no:
Oncotarget;9;
Availability:
Full text availableKeywords:
Bevacizumab, Predictive biomarkers, Metastatic colorectal cancer, Vasculature, InflammationSubject (TCD):
Cancer , Immunology, Inflammation & InfectionDOI:
http://dx.doi.org/10.18632Metadata
Show full item recordLicences: